2nd Quarter - Report

BIODESIX for BIODESIX

Firm
Client
Income
—
Expenses
$58,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

- Discussion draft to reform Section 101 of the Patent Act concerning patent eligibility

LobbyistCovered position, as disclosed
KATIE JONES —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

-Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93) -payment of laboratory tests (S.1895; H.R. 3630) -Update packaging policy for protein-based tests (CY 2018 OPPS/ASC final rule)

LobbyistCovered position, as disclosed
KATIE JONES —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3630 (116th), S. 1895 (116th)

Medical/Disease Research/Clinical Labs MED

-Regulation of laboratory developed tests (Verifying Accurate, Leading-edge IVCT Development (VALID) Act discussion draft)

LobbyistCovered position, as disclosed
KATIE JONES —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.